Published

Harm reduction practises for users of psychedelic drugs: a scoping review.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Harm reduction journal
Date: 2025-10-03
Source: PubMed
DOI: 10.1186/s12954-025-01264-2
PubMed: 41044617

Authors

Dutton C North E Chun Tie Y Oliva J Skeffington P

Watch author

Derived topics and classifications

psilocybin Review Article Safety Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.Expert opinion on pharmacotherapy · 2026-04-01 Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11 Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2025-12-01 A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From MethamphetamineClinicalTrials.gov · 2025-10-07 The Emerging Use of Psilocybin in Adult Populations with Alcohol Use Disorder: A Scoping ReviewPreprints.org · 2025-06-19 An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept StudyClinicalTrials.gov · 2025-03-19 High Risk, Low Key: The New Face of Drug Use.Substance use: research and treatment · 2025-01-01 The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.CNS spectrums · 2024-12-01